# Peter J Bostrm

### List of Publications by Citations

Source: https://exaly.com/author-pdf/8927057/peter-j-bostrom-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

142<br/>papers2,803<br/>citations29<br/>h-index47<br/>g-index154<br/>ext. papers3,566<br/>ext. citations4.7<br/>avg, IF4.86<br/>L-index

#	Paper	IF	Citations
142	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2299-2305	2.2	153
141	Genomic Predictors of Outcome in Prostate Cancer. European Urology, 2015, 68, 1033-44	10.2	136
140	Risk factors for mortality and morbidity related to radical cystectomy. <i>BJU International</i> , <b>2009</b> , 103, 191	- <b>6</b> .6	119
139	A new and highly prognostic system to discern T1 bladder cancer substage. <i>European Urology</i> , <b>2012</b> , 61, 378-84	10.2	117
138	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. <i>BJU International</i> , <b>2011</b> , 108, 24-30	5.6	90
137	Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study. <i>Journal of Magnetic Resonance Imaging</i> , <b>2017</b> , 46, 184-193	5.6	82
136	Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. <i>BJU International</i> , <b>2012</b> , 110, 804-11	5.6	73
135	Nutraceuticals and prostate cancer prevention: a current review. <i>Nature Reviews Urology</i> , <b>2010</b> , 7, 21-30	) 5.5	70
134	Evaluation of different mathematical models for diffusion-weighted imaging of normal prostate and prostate cancer using high b-values: a repeatability study. <i>Magnetic Resonance in Medicine</i> , <b>2015</b> , 73, 1988-98	4.4	64
133	Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. <i>European Urology</i> , <b>2013</b> , 63, 379-85	10.2	63
132	Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). <i>Journal of Magnetic Resonance Imaging</i> , <b>2017</b> , 46, 1089-109	9 <b>5</b> .6	62
131	The FGFR3 mutation is related to favorable pT1 bladder cancer. <i>Journal of Urology</i> , <b>2012</b> , 187, 310-4	2.5	61
130	Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk?. <i>European Urology</i> , <b>2007</b> , 52, 973-82	10.2	61
129	European Association of Urology (@Uroweb) recommendations on the appropriate use of social media. <i>European Urology</i> , <b>2014</b> , 66, 628-32	10.2	54
128	Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. <i>BJU International</i> , <b>2011</b> , 108, E237-44	5.6	51
127	Prospective evaluation of F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 355-364	8.8	49
126	Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. <i>BJU International</i> , <b>2012</b> , 110, 1169-76	5.6	48

125	Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder. <i>International Journal of Cancer</i> , <b>2000</b> , 88, 417-423	7.5	47
124	Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization. <i>PLoS ONE</i> , <b>2019</b> , 14, e0217702	3.7	46
123	Staging and Staging Errors in Bladder Cancer. European Urology Supplements, 2010, 9, 2-9	0.9	45
122	Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction. <i>Magnetic Resonance in Medicine</i> , <b>2017</b> , 77, 1249-1264	4.4	42
121	Mathematical models for diffusion-weighted imaging of prostate cancer using b values up to 2000 s/mm(2): correlation with Gleason score and repeatability of region of interest analysis. <i>Magnetic Resonance in Medicine</i> , <b>2015</b> , 74, 1116-24	4.4	41
120	Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133552	3.7	39
119	Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. <i>European Urology</i> , <b>2019</b> , 76, 586-595	10.2	38
118	Imaging renal cell carcinoma with ultrasonography, CT and MRI. <i>Nature Reviews Urology</i> , <b>2010</b> , 7, 311-2.	5 5.5	34
117	Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro. <i>American Journal of Pathology</i> , <b>1999</b> , 154, 755-65	5.8	34
116	Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. <i>Modern Pathology</i> , <b>2016</b> , 29, 1565-15	7 <sup>4.8</sup>	32
115	Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy. <i>Journal of Urology</i> , <b>2008</b> , 179, 91-5; discussion 95	2.5	32
114	Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155901	3.7	30
113	Non-muscle-invasive bladder cancer: a vision for the future. <i>Scandinavian Journal of Urology</i> , <b>2017</b> , 51, 87-94	1.6	28
112	SORLA regulates endosomal trafficking and oncogenic fitness of HER2. <i>Nature Communications</i> , <b>2019</b> , 10, 2340	17.4	28
111	Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies. <i>PLoS ONE</i> , <b>2013</b> , 8, e76190	3.7	27
110	Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells. <i>Pathology</i> , <b>2001</b> , 33, 469-74	1.6	27
109	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , <b>2016</b> , 196, 1627-1633	2.5	26
108	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002813	11.6	25

107	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). <i>European Urology Oncology</i> , <b>2020</b> , 4, 971-971	6.7	25
106	Does patient age affect survival after radical cystectomy?. <i>BJU International</i> , <b>2012</b> , 110, E486-93	5.6	24
105	Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with Ga-PSMA-11 PET/MRI in men with treatment-nalle prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 665-673	8.8	23
104	Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140671	3.7	22
103	Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , <b>2016</b> , 2, 101-109	1	22
102	Diffusion-weighted imaging of prostate cancer: effect of b-value distribution on repeatability and cancer characterization. <i>Magnetic Resonance Imaging</i> , <b>2015</b> , 33, 1212-1218	3.3	21
101	Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. <i>European Urology</i> , <b>2019</b> , 76, 430-434	10.2	21
100	Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Gufin (BCG) or alternating BCG and interferon-2b instillations: prospective	10.2	20
99	Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols. <i>World Journal of Urology</i> , <b>2013</b> , 31, 161-7	4	20
98	Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. <i>BJU International</i> , <b>2012</b> , 109, 70-6	5.6	20
97	Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Gufin. <i>Urology Annals</i> , <b>2011</b> , 3, 119-26	1	20
96	Interferon-alpha inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. <i>Urological Research</i> , <b>2001</b> , 29, 20-4		20
95	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?. <i>European Urology</i> , <b>2020</b> , 78, 682-687	10.2	20
94	C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial). <i>Cancer Imaging</i> , <b>2018</b> , 18, 25	5.6	18
93	FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2014</b> , 465, 207-13	5.1	17
92	Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. <i>Carcinogenesis</i> , <b>2019</b> , 40, 84-92	4.6	17
91	ANO7 is associated with aggressive prostate cancer. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2479-248	<b>87.</b> 5	17
90	Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study. <i>European Urology Oncology</i> , <b>2018</b> , 1, 525-530	6.7	16

# (2016-2014)

89	High-intensity physical activity, stable relationship, and high education level associate with decreasing risk of erectile dysfunction in 1,000 apparently healthy cardiovascular risk subjects.  Journal of Sexual Medicine, 2014, 11, 2277-84	1.1	15	
88	Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials). <i>Journal of Magnetic Resonance Imaging</i> ,	5.6	15	
87	Intravesical Bacillus Calmette-Guffin Versus Combination of Epirubicin and Interferon-🏻 in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. <i>European Urology</i> , <b>2016</b> , 70, 341-7	10.2	15	
86	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. <i>European Urology Focus</i> , <b>2018</b> , 4, 995-1001	5.1	14	
85	Relaxation along fictitious field, diffusion-weighted imaging, and T2 mapping of prostate cancer: Prediction of cancer aggressiveness. <i>Magnetic Resonance in Medicine</i> , <b>2016</b> , 75, 2130-40	4.4	14	
84	Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 140-52	7.5	14	
83	New prostate cancer grade grouping system predicts survival after radical prostatectomy. <i>Human Pathology</i> , <b>2018</b> , 75, 159-166	3.7	13	
82	Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. <i>European Urology Oncology</i> , <b>2020</b> , 3, 648-656	6.7	13	
81	A Prospective Comparison of F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed	6.7	13	
80	Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. <i>BMC Urology</i> , <b>2016</b> , 16, 10	2.2	12	
79	Rotating frame relaxation imaging of prostate cancer: Repeatability, cancer detection, and Gleason score prediction. <i>Magnetic Resonance in Medicine</i> , <b>2016</b> , 75, 337-44	4.4	12	
78	Correlation between F-1-amino-3-fluorocyclobutane-1-carboxylic acid (F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. <i>EJNMMI Research</i> , <b>2019</b> , 9, 50	3.6	11	
77	Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. <i>Scandinavian Journal of Urology</i> , <b>2019</b> , 53, 295-302	1.6	11	
76	Time trends and occupational variation in the incidence of testicular cancer in the Nordic countries. <i>BJU International</i> , <b>2018</b> , 122, 384-393	5.6	11	
75	Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>2009</b> , 43, 357-64		11	
74	Protodynamic therapy for bladder cancer: in vitro results of a novel treatment concept. <i>BJU International</i> , <b>2009</b> , 104, 1233-8	5.6	11	
73	Repeatability of radiomics and machine learning for DWI: Short-term repeatability study of 112 patients with prostate cancer. <i>Magnetic Resonance in Medicine</i> , <b>2020</b> , 83, 2293-2309	4.4	11	
72	Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care. <i>Scandinavian Journal of Urology</i> , <b>2016</b> , 50, 149-54	1.6	11	

71	Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort. <i>European Urology Focus</i> , <b>2019</b> , 5, 443-448	5.1	11
70	Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, 807-819	5.7	11
69	Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA. <i>Acta Oncolgica</i> , <b>2017</b> , 56, 971-977	3.2	9
68	IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy. <i>Journal of Magnetic Resonance Imaging</i> , <b>2019</b> , 50, 1641-1650	5.6	9
67	Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study. <i>BJU International</i> , <b>2018</b> , 122, 203-210	5.6	9
66	Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study. <i>World Journal of Urology</i> , <b>2021</b> , 39, 1879-1887	4	9
65	Prediction of complication related death after radical cystectomy for bladder cancer with machine learning methodology. <i>Scandinavian Journal of Urology</i> , <b>2019</b> , 53, 325-331	1.6	8
64	Progress towards a Nordic standard for the investigation of hematuria: 2019. <i>Scandinavian Journal of Urology</i> , <b>2019</b> , 53, 1-6	1.6	8
63	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 12682	4.9	7
62	The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis. <i>Prostate</i> , <b>2018</b> , 78, 583-594	4.2	7
61	Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 255.e15-22	2.8	7
60	Prospective comparison of F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2951-2959	8.8	7
59	External validation of a biomarker based pre-cystectomy algorithm to predict nonorgan confined urothelial cancers. <i>Journal of Urology</i> , <b>2012</b> , 187, 840-4	2.5	6
58	Seminal vesicles and urinary bladder as sites of aromatization of androgens in men, evidenced by a CYP19A1-driven luciferase reporter mouse and human tissue specimens. <i>FASEB Journal</i> , <b>2013</b> , 27, 1342	2-509	6
57	Optimal timing of radical cystectomy in T1 high-grade bladder cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 1891-902	3.5	6
56	Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records. <i>Journal of the American Medical Informatics</i>	8.6	6
55	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , <b>2016</b> , 2, 263-272	1	6
54	Erectile dysfunction cannot be used in primary screening of pre-diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2015</b> , 108, e60-2	7.4	5

## (2016-2020)

53	Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results. <i>European Urology Open Science</i> , <b>2020</b> , 22, 79-87	0.9	5
52	The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 891-898	7.5	5
51	Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. <i>European Urology Focus</i> , <b>2021</b> , 7, 522-531	5.1	5
50	Diffusion weighted imaging of prostate cancer: Prediction of cancer using texture features from parametric maps of the monoexponential and kurtosis functions <b>2016</b> ,		5
49	Adverse Events During Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , <b>2019</b> , 5, 273-279	1	5
48	Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial. <i>World Journal of Urology</i> , <b>2020</b> , 38, 1001-1007	4	5
47	Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates. <i>BMC Urology</i> , <b>2015</b> , 15, 88	2.2	4
46	Tournament leave-pair-out cross-validation for receiver operating characteristic analysis. <i>Statistical Methods in Medical Research</i> , <b>2019</b> , 28, 2975-2991	2.3	4
45	rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , <b>2019</b> , 39, 5353-5359	2.3	4
44	Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 16.e1-16.e7	2.8	4
43	Kinetic analysis and optimisation of F-rhPSMA-7.3 PET imaging of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 3723-3731	8.8	4
42	Bulbourethral gland adenocarcinoma in a 25-year-old man without comorbidities: radical resection of proximal urethrae with Mitrofanoff-type appendicovesicostomy. <i>Scandinavian Journal of Urology</i> , <b>2014</b> , 48, 405-9	1.6	3
41	Upper urinary tract cancerchallenges for the urologist. <i>Journal of Urology</i> , <b>2007</b> , 178, 12-3	2.5	3
40	Vasectomy and the risk of prostate cancer in a Finnish nationwide population-based cohort. <i>Cancer Epidemiology</i> , <b>2020</b> , 64, 101631	2.8	3
39	Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method. <i>Journal of Magnetic Resonance Imaging</i> , <b>2016</b> , 44, 1405-1414	5.6	3
38	Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps. <i>European Radiology</i> , <b>2021</b> , 31, 379-391	8	3
37	Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy. <i>Scientific Reports</i> , <b>2016</b> , 6, 36161	4.9	2
36	Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 80-80	2.2	2

35	Computerized histomorphometric features of glandular architecture predict risk of biochemical recurrence following radical prostatectomy: A multisite study <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5060-5060	2.2	2
34	Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machine-Learning Techniques. <i>Journal of Magnetic Resonance Imaging</i> , <b>2020</b> , 51, 1540-1553	5.6	2
33	Reply to Joshua S. Jue and Mahmoud Alameddineß Letter to the Editor re: Juha Knaapila, Ivan Jambor, Ileana Montoya Perez, et al. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. Eur Urol Oncol 2020;3:648-656. European Urology Oncology, 2020, 3, 711-712	6.7	2
32	Critical evaluation of the subcutaneous engraftments of hormone nawe primary prostate cancer.  Translational Andrology and Urology, <b>2020</b> , 9, 1120-1134	2.3	2
31	Prediction of prostate cancer aggressiveness using F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. <i>Scientific Reports</i> , <b>2020</b> , 10, 9407	4.9	2
30	Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer. <i>Acta Radiologica</i> , <b>2021</b> , 62, 1687-1695	2	2
29	Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 481-486	1.6	2
28	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 35	9.8	2
27	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. <i>European Urology Oncology</i> , <b>2021</b> , 4, 289-296	6.7	2
26	Risk factors associated with positive surgical marginsPlocation at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , <b>2021</b> , 39, 4363-4371	4	2
25	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> ,	2.8	2
24	Clinical markers of morbidity, mortality and survival in bladder cancer patients treated with radical cystectomy. A systematic review. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 267-276	1.6	1
23	Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Gufin (BCG) treatment. <i>BJU International</i> , <b>2019</b> , 123, 246-251	5.6	1
22	Reply to Mengxin Lu, Yi Zhang, Yu Xiaoß Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrfh, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4. European Urology, 2019	10.2	1
21	Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 393-393	2.2	1
20	Reply to Xuefeng Liuß Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrfin, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4: Can Patient-derived Cancer Models	10.2	1
19	Re: Antonio C. Westphalen, Charles E. McCulloch, Jordan M. Anaokar, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology 2020;296:76-84: Can the	6.7	1
18	Positive Predictive Value of Prostate MRI in Correlation with Biopsy Findings be Interpreted A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. <i>Scientific Reports</i> , <b>2021</b> , 11, 8650	4.9	1

#### LIST OF PUBLICATIONS

17	Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study. <i>BJU International</i> , <b>2021</b> ,	5.6	1
16	Uptake of F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2021</b> ,	3.9	1
15	Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. <i>International Journal of Hyperthermia</i> , <b>2019</b> , 36, 915-925	3.7	О
14	How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database. <i>Acta Radiologica Open</i> , <b>2021</b> , 10, 20584601211060707	1.2	O
13	Decreased forced expiratory volume in first second is associated with erectile dysfunction in apparently healthy men. A preliminary study. <i>International Journal of Impotence Research</i> , <b>2020</b> , 32, 420-	- <del>2</del> 25	0
12	Familial aggregation of testicular cancer among early-onset cancer survivors. A prospective observational cohort data from Finland. <i>Cancer Epidemiology</i> , <b>2020</b> , 69, 101807	2.8	O
11	Response to the Letter to the Editor: Prospective comparison of F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2672-2673	8.8	О
10	Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. <i>Scientific Reports</i> , <b>2021</b> , 11, 13684	4.9	O
9	Visual MRI T-category versus VI-RADS evaluation from multiparametric MRI in the detection of muscle-invasion in patients with suspected bladder cancer: single centre registered clinical trial (MIB-trial). <i>Scandinavian Journal of Urology</i> , <b>2021</b> , 55, 354-360	1.6	О
8	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol <i>BMJ Open</i> , <b>2022</b> , 12, e050	<sup>2</sup> 64	O
7	Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen. <i>journal of applied laboratory medicine, The</i> , <b>2019</b> , 3, 1014-1021	2	
6	Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation. <i>BMC Urology</i> , <b>2020</b> , 20, 25	2.2	
5	A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16003-e1600	<sup>2.2</sup>	
4	Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy nalle men. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 7-13	1.6	
3	Which data are available in central registries on bladder cancer patients in the five Nordic countries. <i>Scandinavian Journal of Urology</i> , <b>2021</b> , 55, 135-141	1.6	
2	Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0) BMJ Open, <b>2022</b> , 12, e053118	3	
1	Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study World Journal of Urology, <b>2022</b> , 1	4	